---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-026094"
form_type: "8-K"
ticker: null
cik: "0001840904"
company_name: "ATAI Life Sciences N.V."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:32:26.161043+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CEO Florian Brand to step down by YE2024; Dr. Rao to succeed; Q1 net loss $26.7M

## Summary
- CEO Florian Brand to step down by Dec 31, 2024; will serve as Co-CEO from June 1 until then.
- Co-Founder Dr. Srinivas Rao appointed Co-CEO effective June 1, 2024; to become CEO by YE2024.
- Q1 2024 net loss $26.7M ($33.1M in Q1 2023); R&D expenses $11.5M, down from $19.3M YoY.
- Cash, equivalents and short-term investments $121.3M at March 31, 2024; sufficient into 2026.
- VLS-01 Phase 1b data and BPL-003 Phase 2b TRD topline data both expected in 2H 2024.

## SEC filing metadata
- accession: 0001140361-24-026094
- form_type: 8-K
- cik: 0001840904
- company_name: ATAI Life Sciences N.V.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840904/000114036124026094/0001140361-24-026094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840904/000114036124026094/ef20029167_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-026094
- JSON: https://secwatch.observer/filing/0001140361-24-026094.json
- Plain text: https://secwatch.observer/filing/0001140361-24-026094.txt

## Key facts
- Earnings Releases
  ATAI Life Sciences N.V. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 15, 2024, ATAI Life Sciences N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840904/000114036124026094/0001140361-24-026094-index.htm
- Executive change
  Srinivas Rao was appointed as Co-Chief Executive Officer at ATAI Life Sciences N.V..
  - Action: appointed
  - Role: Co-Chief Executive Officer
  source text: Effective June 1, 2024, Dr. Srinivas Rao was appointed the Company's Co-Chief Executive Officer and designated as co-principal executive officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840904/000114036124026094/0001140361-24-026094-index.htm
- Executive change
  Florian Brand changed role as Co-Chief Executive Officer at ATAI Life Sciences N.V..
  - Role: Co-Chief Executive Officer
  source text: Mr. Brand will serve as Co-Chief Executive Officer of the Company from June 1, 2024 through December 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840904/000114036124026094/0001140361-24-026094-index.htm
- Executive change
  Florian Brand departed as Chief Executive Officer at ATAI Life Sciences N.V..
  - Action: stepping down
  - Role: Chief Executive Officer
  source text: at which time he will be stepping down from his position as the Company's Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840904/000114036124026094/0001140361-24-026094-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.